Arecor Therapeutics PLC Arecor's Polysaccharide Vaccine Patent Upheld (6478O)
11 October 2021 - 7:18PM
UK Regulatory
TIDMAREC
RNS Number : 6478O
Arecor Therapeutics PLC
11 October 2021
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
ARECOR'S POLYSACCHARIDE VACCINE PATENT UPHELD
Cambridge, UK, 11 October 2021: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, continues to build a strong patent
portfolio protecting its proprietary Arestat(TM) technology. Arecor
is pleased to announce that its European patent EP2457590 on
polysaccharide vaccines has been successfully upheld following
opposition appeal proceedings filed by GlaxoSmithKline Biologicals
SA (GSK) at the Boards of Appeal of the European Patent Office.
As part of the Intellectual Property legislation in Europe,
patents can be opposed by other companies, within a certain period
of time following their formal grant. The opposition process can
result in the patent being revoked, amended or upheld in its
original form. In accordance with this process, at an oral hearing
on 1 October 2021, the Boards of Appeal, which is the final
judicial instance in the procedures, considered an appeal filed by
GSK in response to an earlier ruling in Arecor's favour and decided
to dismiss the appeal, upholding the patent as granted.
Arecor's European patent EP2457590 protects novel compositions
of a specific type of vaccines, called polysaccharide vaccines.
Examples of polysaccharide vaccines are vaccines that are used to
protect against Meningitis or Pneumonia. Such products are known to
degrade over time, leading to gradual loss of potency. Arecor's
novel compositions protected by this patent, prevent such
degradation and enable the development of improved polysaccharide
vaccines. This includes more convenient dosage forms that can be
used outside the cold chain, thereby increasing the efficiency of
immunisation coverage.
Arecor has invested in building a strong patent portfolio to
protect the Arestat(TM) technology platform. The Group's
intellectual property portfolio currently comprises 33 patent
families, including >50 granted patents in Europe in the US and
in other key territories.
Arecor's proprietary formulation technology, Arestat(TM),
enables superior product profiles across a broad range of
therapies, including various types of biopharmaceuticals, specialty
hospital products as well as vaccine compositions with improved
stability. Arecor partners with leading pharmaceutical and
biotechnology companies to deliver enhanced formulations of their
therapeutic products under a technology licensing model, and is
also developing an internal portfolio of proprietary products in
diabetes and other indications.
Dr Jan Jezek, Chief Scientific Officer at Arecor, commented :
"We are delighted about the successful outcome of this appeal.
Having developed a highly innovative formulation technology, Arecor
has firmly established itself as a world leader in the formulation
of superior therapeutic and vaccine products. The value of our
Arestat(TM) technology platform is underpinned by a comprehensive
patent portfolio built systematically around specific aspects of
our technology, as well as the highly differentiated products
enabled by our technology. Our success in the appeal hearing
demonstrates the value and the strength of our innovative
formulation science and associated intellectual property.
Polysaccharide vaccines represent an important class of vaccines
for preventing infections such as meningitis or pneumonia. Our
proprietary compositions enable formulating such vaccines in a way
that simplifies their administration to patients."
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary formulation technology
platform, Arestat(TM) , we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat (TM) platform is supported by an extensive patent portfolio
.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
REAVFLBFFBLFFBQ
(END) Dow Jones Newswires
October 11, 2021 04:18 ET (08:18 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2023 to Apr 2024
